Step 4 Semaglutide: Moving to the 1.7 mg Dose of Wegovy

Why does the titration stop at 1.7 mg before going higher?

The five-step schedule exists because semaglutide's most common side effects are gastrointestinal, and slower increases give your gut time to adjust. Each four-week period at a lower dose is preparation for the next. By the time you reach 1.7 mg, your system has already been through three adaptations, which is exactly why many people find this step more manageable than the jump from 0.25 mg to 0.5 mg felt at the start.

The 1.7 mg dose is not a therapeutic staging post invented for convenience. It appears in the licensed titration pathway because the clinical trials that led to Wegovy's approval (including the large STEP 1 trial, published in the New England Journal of Medicine) used this exact graduated approach. Rushing through the steps does not produce faster results; it tends to produce more nausea. The four weeks at each level matter.

There is also an individual dimension here. A small number of people on the Wegovy step programme find that 1.7 mg is their highest well-tolerated dose and remain there rather than progressing to 2.4 mg. That decision belongs to your prescriber, made on the basis of how you're tolerating the current dose and how your weight is responding. No titration decision should be self-directed.

What tends to change when you move from 1.0 mg to 1.7 mg?

People who have been through Step 3 at 1.0 mg often describe the move to 1.7 mg as the dose where appetite suppression becomes genuinely difficult to ignore. Portion sizes that felt normal a month ago may now feel like too much. That shift is the medicine working as intended, but it also means protein intake and hydration deserve more attention, not less, at this stage.

The side-effect profile does not change in character at Step 4, but intensity can tick up temporarily. Nausea, loose stools, constipation, reflux and fatigue are all listed in the NHS patient information for semaglutide as common effects, and they tend to be most noticeable in the first few days after a dose increase. For most people they settle within a week to ten days. Eating smaller meals, staying well hydrated and avoiding high-fat foods around injection day are practical habits that can help, your prescriber or the Patient Information Leaflet is the right source for personalised guidance.

One thing worth flagging: if you experience severe, persistent stomach pain that radiates to your back, seek medical help promptly rather than waiting for your next check-in. The MHRA issued specific guidance on acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines, something to be aware of at every dose level, not just higher ones.

How does Step 4 fit into the broader picture of Wegovy's results?

The headline figure most people associate with Wegovy (around 15% average body-weight reduction over 68 weeks) comes from the STEP 1 trial, which used the full titration schedule up to the 2.4 mg maintenance dose. Step 4 at 1.7 mg is, in that sense, the final preparation for the dose that drives the majority of the long-term result. That said, meaningful weight reduction typically begins well before 2.4 mg is reached; many people notice real change during the earlier dose steps.

If you're thinking about what Wegovy costs across a course of treatment, our treatment cost page sets out what a transparent private prescription includes (consultation, clinical review, delivery and aftercare) so you can compare properly rather than on headline price alone.

The full Wegovy overview covers everything from the licensing basis to the higher 7.2 mg dose approved by the MHRA in 2026, if you want the wider context before or after reading about individual steps. And if you're already on Step 5 at 2.4 mg, the considerations shift again, weight plateau, long-term use, and what the NICE guidance says about treatment duration all become relevant.

When should you speak to your prescriber rather than waiting?

A question our prescribers hear regularly: how bad does a side effect have to get before it warrants a call? The honest answer is that it varies, but there are clear categories. Mild nausea that passes in a few days after a dose increase does not need urgent contact. Vomiting that prevents you from keeping fluids down for more than 24 hours does. Severe stomach pain, signs of an allergic reaction (swelling, breathing difficulty, rash), or any sudden change in vision should prompt immediate medical attention.

For anything that sits in the middle (persistent discomfort, a symptom you can't quite categorise, or a question about whether to delay your next injection) the right move is to contact your prescriber directly rather than searching for an answer online. At nume, our support team is available seven days a week, and clinical questions go to the prescribers who reviewed your case. That's the point of aftercare being included rather than bolted on as an extra.

If you haven't yet started treatment and are weighing up whether Wegovy is suitable for your situation, you can read more about how our clinical team approaches these assessments on the clinical team page, or head straight to start your free consultation, your answers are reviewed by a GPhC-registered prescriber the same day, and there's no obligation until a prescription is issued.